Sy Mukherjee, Fortune

Sy Mukherjee

Fortune

New York, NY, United States

Contact Sy

Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.

Start free trial

Recent:
  • Fortune

Recent articles by Sy:

Can Disturbing Graphics Scare People Off Cigarettes?

The FDA is proposing European-style, graphic warnings on cigarette packs to discourage smoking. But will it work? → Read More

A Promising Pair of Ebola Drugs Raises Hopes in Africa

Experimental treatments from Regeneron and Ridgeback Biotherapeutics will now be offered to all Ebola patients in the Congo. → Read More

Novartis Defends $2.1 Million Gene Therapy After FDA Data Manipulation Claims

The FDA said Tuesday that Novartis knew of data inaccuracies in its application for Zolgensma, a gene therapy with a $2.1 million list price. → Read More

Legislating Social Media Addiction: Brainstorm Health

There’s a presidential primary debate on tonight (and I imagine at least a few readers will be checking in on it, given an expected focus on health care). But let’s check in on a more low-key, and likely quixotic, policy quest aligned with the digital health space. A freshman U.S. Senator (Josh Hawley, a Missouri […] → Read More

A $43 Billion Biotech Now Has a Female CEO

Reshma Kewalramani is taking the reins at Vertex Pharmaceuticals from industry veteran Jeff Leiden. → Read More

How CVS Wants to Link Social Care With Health Care

CVS wants to get to the source of social care needs that can affect people's health well outside the doctor's office. → Read More

The Heat Is On. Stay Cool

Remember to keep cool during the upcoming heat wave swamping much of the U.S. → Read More

Protect at All Costs: How the Maker of the World’s Bestselling Drug Keeps Prices Sky-High

Humira has turned AbbVie into a global pharma giant—and the company has aggressively blocked competition to protect its sales. How a blockbuster medication became a case study in what’s killing drug innovation. You may not have any of the conditions Humira treats. But chances are, you’ve heard of it. AbbVie’s flagship therapy, a medicine used to treat a slew of […] → Read More

Genentech’s Deal Spree: Brainstorm Health

Good afternoon, readers. We’re hunkered down and closing the upcoming issue of Fortune today. But in the meantime, I hope you’ll follow along with my colleagues’ outstanding coverage of the equally-outstanding Fortune Brainstorm Tech conference currently taking place in Aspen. And a note below on Genentech’s “hat trick” of deals. Read on for the day’s […] → Read More

The Health Care Leaders in Fortune's 40 Under 40

Meet the health care leaders in Fortune's latest 40 Under 40 list of young entrepreneurs. → Read More

3 Drug Giants Win a Legal Victory Against Trump—For Now

Merck, Amgen, and Eli Lilly have successfully blocked the Trump administration's requirement they post drug prices in T.V. ads. → Read More

Can a Monthly Injection Treat HIV?

GlaxoSmithKline announced that Viiv Healthcare, its HIV-focused arm, will launch trials of a long-acting, once-monthly HIV treatment in U.S. clinics. → Read More

Facebook's Health Crackdown: Brainstorm Health

Facebook said Tuesday it's trying to crack down on misleading health claims on its platform. → Read More

uBiome Has a Leadership Problem Amid FBI Woes: Brainstorm Health

The interim CEO of uBiome is stepping down as the company continues to grapple with an FBI investigation. → Read More

Meet Andrew Yang, the Democratic Candidate Who Wants to Give You $1,000 Each Month

Fortune interviewed Andrew Yang, the long shot presidential hopeful who will be on stage for the Democratic debate, on UBI and other issues. → Read More

Digital Health Startup Omada Snags Another $73 Million in Funding: Brainstorm Health

Omada Health raised $73 million at a reported $600 million valuation for its digital diabetes prevention platform. → Read More

Digital Health Startup Omada Snags Another $73 Million in Funding: Brainstorm Health

Omada Health raised $73 million at a reported $600 million valuation for its digital diabetes prevention platform. → Read More

What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health

AbbVie's acquisition of the Botox maker isn't a great reflection on the state of big pharma innovation. → Read More

What AbbVie's $63 Billion Deal to Buy Allergan Says About the Drug Industry

AbbVie, maker of the world's best-selling drug, is buying Botox maker Allergan in a blockbuster deal. Here's what that says about the state of biopharma. → Read More

What the $63 Billion AbbVie Allergan Deal Says About the Drug Industry: Brainstorm Health

AbbVie's acquisition of the Botox maker isn't a great reflection on the state of big pharma innovation. → Read More